Correction: 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation (Journal of the American College of Cardiology (2019) 74(1) (104–132), (S0735109719302098), (10.1016/j.jacc.2019.01.011));2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society

Journal of the American College of Cardiology

Volumn 74, Issue 1, 2019, Pages 104-132

  January, Craig T ^a   Wann, L Samuel ^a   Calkins, Hugh ^a   Chen, Lin Y ^a   Cigarroa, Joaquin E ^a   Cleveland, Joseph C ^a   Ellinor, Patrick T ^a   Ezekowitz, Michael D ^a   Field, Michael E ^a   Furie, Karen L ^a   Heidenreich, Paul A ^a   Murray, Katherine T ^a   Shea, Julie B ^a   Tracy, Cynthia M ^a   Yancy, Clyde W ^a  

^a NONE

Author keywords

ACC AHA Clinical Practice Guidelines; acute coronary syndrome; anticoagulants; anticoagulation agents; antiplatelet agents; apixaban; atrial fibrillation; atrial flutter; cardioversion; coronary artery disease; coronary heart disease; dabigatran; edoxaban; focused update; hypertension; idarucizumab; myocardial infarction; obesity; percutaneous coronary intervention; risk factors; rivaroxaban; sleep apnea; stents; stroke; thromboembolism; warfarin

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BODY WEIGHT LOSS; CARDIOVERSION; CATHETER ABLATION; HEART ATRIUM APPENDAGE; HEART ATRIUM FLUTTER; HUMAN; MEDICAL SOCIETY; OBESITY; PATIENT CARE; PEER REVIEW; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RISK BENEFIT ANALYSIS; SINUS RHYTHM; THROMBOEMBOLISM; COMPLICATION;

ATRIAL FIBRILLATION; HUMANS; THROMBOEMBOLISM;

EID: 85063005462     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2019.06.034     Document Type: Erratum

References (173)

1. Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine (U.S.). Clinical Practice Guidelines We Can Trust. 2011, National Academies Press, Washington, DC.
2. Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine (U.S.). Finding What Works in Health Care: Standards for Systematic Reviews. 2011, National Academies Press, Washington, DC.
3. Anderson, J.L., Heidenreich, P.A., Barnett, P.G., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2304–2322.
4. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. American College of Cardiology and American Heart Association. 2010. Available at: http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf and http://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf. Accessed October 31, 2018.
5. Halperin, J.L., Levine, G.N., Al-Khatib, S.M., et al. Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 67 (2016), 1572–1574.
6. Jacobs, A.K., Anderson, J.L., Halperin, J.L., The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 (2014), 1373–1384.
7. Jacobs, A.K., Kushner, F.G., Ettinger, S.M., et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61 (2013), 213–265.
8. Arnett, D.K., Goodman, R.A., Halperin, J.L., et al. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and US Department of Health and Human Services. J Am Coll Cardiol 64 (2014), 1851–1856.
9. January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 (2014), e1–e76.
10. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. American College of Cardiology and American Heart Association. 2010. Available at: http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf and http://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf. Accessed October 31, 2018.
11. Halperin, J.L., Levine, G.N., Al-Khatib, S.M., et al. Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 67 (2016), 1572–1574.
12. Jacobs, A.K., Kushner, F.G., Ettinger, S.M., et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61 (2013), 213–265.
13. Di Biase, L., Use of direct oral anticoagulants in patients with atrial fibrillation and valvular heart lesions. J Am Heart Assoc, 5, 2016, e002776.
14. Ezekowitz, M.D., Nagarakanti, R., Noack, H., et al. Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation 134 (2016), 589–598.
15. Pan, K.-L., Singer, D.E., Ovbiagele, B., et al. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. J Am Heart Assoc, 6, 2017, e005835.
16. Floyd, C.N., Ferro, A., Indications for anticoagulant and antiplatelet combined therapy. BMJ, 359, 2017, j3782.
17. Lip, G.Y.H., Nieuwlaat, R., Pisters, R., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 137 (2010), 263–272.
18. Olesen, J.B., Torp-Pedersen, C., Hansen, M.L., et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 107 (2012), 1172–1179.
19. Mason, P.K., Lake, D.E., DiMarco, J.P., et al. Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. Am J Med, 125, 2012, 603 e1-6.
20. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
21. Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
22. Granger, C.B., Alexander, J.H., McMurray, J.J.V., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
23. Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
24. Matchar, D.B., Jacobson, A., Dolor, R., et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med 363 (2010), 1608–1620.
25. Ezekowitz, M.D., James, K.E., Radford, M.J., et al. Initiating and maintaining patients on warfarin anticoagulation: the importance of monitoring. J Cardiovasc Pharmacol Ther 4 (1999), 3–8.
26. Hirsh, J., Fuster, V., Guide to anticoagulant therapy. Part 2: oral anticoagulants. American Heart Association. Circulation 89 (1994), 1469–1480.
27. Cannegieter, S.C., Rosendaal, F.R., Wintzen, A.R., et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333 (1995), 11–17.
28. Acar, J., Iung, B., Boissel, J.P., et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 94 (1996), 2107–2112.
29. Hering, D., Piper, C., Bergemann, R., et al. Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study. Chest 127 (2005), 53–59.
30. Nishimura, R.A., Otto, C.M., Bonow, R.O., et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), e57–e185.
31. Nishimura, R.A., Otto, C.M., Bonow, R.O., et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 135 (2017), e1159–e1195.
32. Ahmad, Y., Lip, G.Y.H., Apostolakis, S., New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Expert Rev Cardiovasc Ther 10 (2012), 1471–1480.
33. Chiang, C.-E., Naditch-Brûlé, L., Murin, J., et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 5 (2012), 632–639.
34. Flaker, G., Ezekowitz, M., Yusuf, S., et al. Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. J Am Coll Cardiol 59 (2012), 854–855.
35. Hohnloser, S.H., Duray, G.Z., Baber, U., et al. Prevention of stroke in patients with atrial fibrillation: current strategies and future directions. Eur Heart J 10 (2007), H4–H10.
36. Aguilar, M.I., Hart, R., Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev, 2005, CD001927.
37. Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
38. Winkelmayer, W.C., Liu, J., Setoguchi, S., et al. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 6 (2011), 2662–2668.
39. Bohula, E.A., Giugliano, R.P., Ruff, C.T., et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation 134 (2016), 24–36.
40. Khoury, T., Ayman, A.R., Cohen, J., et al. The complex role of anticoagulation in cirrhosis: an updated review of where we are and where we are going. Digestion 93 (2016), 149–159.
41. Bonde, A.N., Lip, G.Y.H., Kamper, A.-L., et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 64 (2014), 2471–2482.
42. Siontis, K.C., Zhang, X., Eckard, A., et al. Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the United States. Circulation 138 (2018), 1519–1529.
43. Andersson, T., Magnuson, A., Bryngelsson, I.-L., et al. Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without concomitant diseases: a nationwide cohort study of 9519 patients. Int J Cardiol 177 (2014), 91–99.
44. Fang, M.C., Singer, D.E., Chang, Y., et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 112 (2005), 1687–1691.
45. Pancholy, S.B., Sharma, P.S., Pancholy, D.S., et al. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol 113 (2014), 485–490.
46. Mikkelsen, A.P., Lindhardsen, J., Lip, G.Y.H., et al. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J Thromb Haemost 10 (2012), 1745–1751.
47. Wagstaff, A.J., Overvad, T.F., Lip, G.Y.H., et al. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. QJM 107 (2014), 955–967.
48. Hariharan, S., Madabushi, R., Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol 52 (2012), 119S–125S.
49. Lehr, T., Haertter, S., Liesenfeld, K.-H., et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 52 (2012), 1373–1378.
50. Connolly, S.J., Eikelboom, J., Joyner, C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 364 (2011), 806–817.
51. Eikelboom, J.W., Connolly, S.J., Brueckmann, M., et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369 (2013), 1206–1214.
52. Quinn, G.R., Severdija, O.N., Chang, Y., et al. Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation. Circulation 135 (2017), 208–219.
53. Rivera-Caravaca, J.M., Roldán, V., Esteve-Pastor, M.A., et al. Prediction of long-term net clinical outcomes using the TIMI-AF score: comparison with CHA2DS2-VASc and HAS-BLED. Am Heart J 197 (2018), 27–34.
54. Fanola, C.L., Giugliano, R.P., Ruff, C.T., et al. A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. Eur Heart J 38 (2017), 888–896.
55. Philippart, R., Brunet-Bernard, A., Clementy, N., et al. CHA2DS2-VASc score for predicting stroke and thromboembolism in patients with AF and biological valve prosthesis. J Am Coll Cardiol 67 (2016), 343–344.
56. Carnicelli, A.P., De Caterina, R., Halperin, J.L., et al. Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation 135 (2017), 1273–1275.
57. Pokorney, S.D., Rao, M.P., Wojdyla, D.M., et al. Apixaban use in patients with atrial fibrillation with bioprosthetic valves: insights from ARISTOTLE. [abstract 17277] Circulation, 132(suppl 3), 2015, A17277.
58. Puskas, J., Gerdisch, M., Nichols, D., et al. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg 147 (2014), 1202–1210 discussion 1210-1.
59. ELIQUIS (apixaban) [package insert], 2012, Bristol-Myers Squibb Company, Princeton, NJ.
60. Savaysa [package insert], 2015, Daiichi Sankyo, Inc., Parsippany, NJ.
61. Nielsen, P.B., Skjøth, F., Overvad, T.F., et al. Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc?. Circulation 137 (2018), 832–840.
62. You, J.J., Singer, D.E., Howard, P.A., et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141 (2012), e531S–e575.
63. U.S. Renal Data System. 2016 USRDS annual data report: epidemiology of kidney disease in the United States. 2016, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
64. Sood, M.M., Komenda, P., Sood, A.R., et al. The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis?. Chest 136 (2009), 1128–1133.
65. Nochaiwong, S., Ruengorn, C., Awiphan, R., et al. Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis. Open Heart, 3, 2016, e000441.
66. Deal, E.N., Pope, H., Ross, W., Apixaban use among patients with severe renal impairment. Ann Pharmacother, 48, 2014, 1667.
67. Stanton, B.E., Barasch, N.S., Tellor, K.B., Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. Pharmacotherapy 37 (2017), 412–419.
68. Mavrakanas, T.A., Samer, C.F., Nessim, S.J., et al. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol 28 (2017), 2241–2248.
69. Reed, D., Palkimas, S., Hockman, R., et al. Safety and effectiveness of apixaban compared to warfarin in dialysis patients. Res Pract Thromb Haemost 2 (2018), 291–298.
70. Fauchier, L., Clementy, N., Bisson, A., et al. Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated?. Stroke 47 (2016), 1831–1836.
71. Dias, C., Moore, K.T., Murphy, J., et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis. Am J Nephrol 43 (2016), 229–236.
72. De Vriese, A.S., Caluwé, R., Bailleul, E., et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis 66 (2015), 91–98.
73. Chan, K.E., Edelman, E.R., Wenger, J.B., et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 131 (2015), 972–979.
74. Van de Werf, F., Brueckmann, M., Connolly, S.J., et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J 163 (2012), 931–937.e1.
75. Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
76. Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
77. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
78. Granger, C.B., Alexander, J.H., McMurray, J.J.V., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
79. Pan, K.-L., Singer, D.E., Ovbiagele, B., et al. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. J Am Heart Assoc, 6, 2017, e005835.
80. Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383 (2014), 955–962.
81. Abraham, N.S., Noseworthy, P.A., Yao, X., et al. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology 152 (2017), 1014–1022.e1.
82. Graham, D.J., Reichman, M.E., Wernecke, M., et al. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 176 (2016), 1662–1671.
83. Larsen, T.B., Skjøth, F., Nielsen, P.B., et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ, 353, 2016, i3189.
84. Lip, G.Y.H., Keshishian, A., Kamble, S., et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost 116 (2016), 975–986.
85. Noseworthy, P.A., Yao, X., Abraham, N.S., et al. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest 150 (2016), 1302–1312.
86. Yao, X., Abraham, N.S., Sangaralingham, L.R., et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc, 5, 2016, e003725.
87. Ntaios, G., Papavasileiou, V., Makaritsis, K., et al. Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke 48 (2017), 2494–2503.
88. Bai, Y., Shi, X.-B., Ma, C.-S., et al. Meta-analysis of effectiveness and safety of oral anticoagulants in atrial fibrillation with focus on apixaban. Am J Cardiol 120 (2017), 1689–1695.
89. Calkins, H., Willems, S., Gerstenfeld, E.P., et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med 376 (2017), 1627–1636.
90. Yao, X., Tangri, N., Gersh, B.J., et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 70 (2017), 2621–2632.
91. Lau, W.C.Y., Chan, E.W., Cheung, C.-L., et al. Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation. JAMA 317 (2017), 1151–1158.
92. Kent, A.P., Brueckmann, M., Fraessdorf, M., et al. Concomitant oral anticoagulant and nonsteroidal anti-inflammatory drug therapy in patients with atrial fibrillation. J Am Coll Cardiol 72 (2018), 255–267.
93. Douketis, J.D., Spyropoulos, A.C., Kaatz, S., et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 373 (2015), 823–833.
94. Pollack, C.V. Jr., Reilly, P.A., van Ryn, J., et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 377 (2017), 431–441.
95. Siegal, D.M., Curnutte, J.T., Connolly, S.J., et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373 (2015), 2413–2424.
96. Connolly, S.J., Milling, T.J. Jr., Eikelboom, J.W., et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375 (2016), 1131–1141.
97. Reddy, V.Y., Sievert, H., Halperin, J., et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 312 (2014), 1988–1998.
98. Holmes, D.R. Jr., Kar, S., Price, M.J., et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 64 (2014), 1–12.
99. Holmes, D.R. Jr., Doshi, S.K., Kar, S., et al. Left atrial appendage closure as an alternative to warfarin for stroke Prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 65 (2015), 2614–2623.
100. Reddy, V.Y., Gibson, D.N., Kar, S., et al. Post-approval U.S. experience with left atrial appendage closure for stroke prevention in atrial fibrillation. J Am Coll Cardiol 69 (2017), 253–261.
101. Boersma, L.V.A., Schmidt, B., Betts, T.R., et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J 37 (2016), 2465–2474.
102. Reddy, V.Y., Möbius-Winkler, S., Miller, M.A., et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 61 (2013), 2551–2556.
103. Boersma, L.V., Ince, H., Kische, S., et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial. Heart Rhythm 14 (2017), 1302–1308.
104. Holmes, D.R., Reddy, V.Y., Buchbinder, M., et al. The assessment of the Watchman device in patients unsuitable for oral anticoagulation (ASAP-TOO) trial. Am Heart J 189 (2017), 68–74.
105. Friedman, D.J., Piccini, J.P., Wang, T., et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing concomitant cardiac surgery. JAMA 319 (2018), 365–374.
106. Melduni, R.M., Schaff, H.V., Lee, H.-C., et al. Impact of left atrial appendage closure during cardiac surgery on the occurrence of early postoperative atrial fibrillation, stroke, and mortality: a propensity score-matched analysis of 10 633 patients. Circulation 135 (2017), 366–378.
107. Gallagher, M.M., Hennessy, B.J., Edvardsson, N., et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol 40 (2002), 926–933.
108. Jaber, W.A., Prior, D.L., Thamilarasan, M., et al. Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: a transesophageal echocardiographic study. Am Heart J 140 (2000), 150–156.
109. You, J.J., Singer, D.E., Howard, P.A., et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141 (2012), e531S–e575.
110. Nagarakanti, R., Ezekowitz, M.D., Oldgren, J., et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 123 (2011), 131–136.
111. Piccini, J.P., Stevens, S.R., Lokhnygina, Y., et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 61 (2013), 1998–2006.
112. Flaker, G., Lopes, R.D., Al-Khatib, S.M., et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol 63 (2014), 1082–1087.
113. Cappato, R., Ezekowitz, M.D., Klein, A.L., et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 35 (2014), 3346–3355.
114. Goette, A., Merino, J.L., Ezekowitz, M.D., et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 388 (2016), 1995–2003.
115. Pallisgaard, J.L., Lindhardt, T.B., Hansen, M.L., et al. Cardioversion and risk of adverse events with dabigatran versus warfarin—a nationwide cohort study. PLoS ONE, 10, 2015, e0141377.
116. Plitt, A., Ezekowitz, M.D., De Caterina, R., et al. Cardioversion of atrial fibrillation in ENGAGE AF-TIMI 48. Clin Cardiol 39 (2016), 345–346.
117. Dentali, F., Botto, G.L., Gianni, M., et al. Efficacy and safety of direct oral anticoagulants in patients undergoing cardioversion for atrial fibrillation: a systematic review and meta-analysis of the literature. Int J Cardiol 185 (2015), 72–77.
118. Ezekowitz, M.D., Pollack, C.V. Jr., Halperin, J.L., et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J 39 (2018), 2959–2971.
119. Airaksinen, K.E.J., Grönberg, T., Nuotio, I., et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol 62 (2013), 1187–1192.
120. Garg, A., Khunger, M., Seicean, S., et al. Incidence of thromboembolic complications within 30 days of electrical cardioversion performed within 48 hours of atrial fibrillation onset. J Am Coll Cardiol EP 2 (2016), 487–494.
121. Klein, A.L., Grimm, R.A., Murray, R.D., et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344 (2001), 1411–1420.
122. von Besser, K., Mills, A.M., Is discharge to home after emergency department cardioversion safe for the treatment of recent-onset atrial fibrillation?. Ann Emerg Med 58 (2011), 517–520.
123. Pfizer, Study of the blood thinner, apixaban, for patients who have an abnormal heart rhythm (atrial fibrillation) and expected to have treatment to put them back into a normal heart rhythm (cardioversion) (EMANATE). Available at: https://www.clinicaltrials.gov Identifier: NCT02100228. Accessed November 22, 2017.
124. Nuotio, I., Hartikainen, J.E.K., Grönberg, T., et al. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA 312 (2014), 647–649.
125. Bah, A., Nuotio, I., Gronberg, T., et al. Sex, age, and time to cardioversion. Risk factors for cardioversion of acute atrial fibrillation from the FinCV study. Ann Med 49 (2017), 254–259.
126. Kleemann, T., Becker, T., Strauss, M., et al. Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation < 48 hours undergoing cardioversion: value of transesophageal echocardiography to guide cardioversion. J Am Soc Echocardiogr 22 (2009), 1403–1408.
127. Marrouche, N.F., Brachmann, J., Andresen, D., et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 378 (2018), 417–427.
128. Di Biase, L., Mohanty, P., Mohanty, S., et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation 133 (2016), 1637–1644.
129. Prabhu, S., Taylor, A.J., Costello, B.T., et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI Study. J Am Coll Cardiol 70 (2017), 1949–1961.
130. Al Halabi, S., Qintar, M., Hussein, A., et al. Catheter ablation for atrial fibrillation in heart failure patients: a meta-analysis of randomized controlled trials. J Am Coll Cardiol EP 1 (2015), 200–209.
131. Packer, D.L., Mark, D.B., Robb, R.A., et al. Catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation (CABANA) trial: study rationale and design. Am Heart J 199 (2018), 192–199.
132. Packer, D.L., Mark, D.B., Robb, R.A., et al. Catheter ablation vs. antiarrhythmic drug therapy for atrial fibrillation: the results of the Cabana Multicenter International Randomized Clinical Trial. [abstract B-LBCT01-05] Heart Rhythm, 15, 2018 940-141.
133. Cannon, C.P., Bhatt, D.L., Oldgren, J., et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377 (2017), 1513–1524.
134. Gibson, C.M., Mehran, R., Bode, C., et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375 (2016), 2423–2434.
135. Dewilde, W.J.M., Oirbans, T., Verheugt, F.W.A., et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381 (2013), 1107–1115.
136. Sarafoff, N., Martischnig, A., Wealer, J., et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 61 (2013), 2060–2066.
137. Jackson, L.R., Ju, C., Zettler, M., et al. Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS Study. J Am Coll Cardiol Intv 8 (2015), 1880–1889.
138. Lamberts, M., Gislason, G.H., Olesen, J.B., et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 62 (2013), 981–989.
139. Rubboli, A., Schlitt, A., Kiviniemi, T., et al. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry. Clin Cardiol 37 (2014), 357–364.
140. Braun, O.Ö., Bico, B., Chaudhry, U., et al. Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. Thromb Res 135 (2015), 26–30.
141. Fiedler, K.A., Maeng, M., Mehilli, J., et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE Trial. J Am Coll Cardiol 65 (2015), 1619–1629.
142. Koskinas, K.C., Räber, L., Zanchin, T., et al. Duration of triple antithrombotic therapy and outcomes among patients undergoing percutaneous coronary intervention. J Am Coll Cardiol Intv 9 (2016), 1473–1483.
143. Crenshaw, B.S., Ward, S.R., Granger, C.B., et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 30 (1997), 406–413.
144. Rathore, S.S., Berger, A.K., Weinfurt, K.P., et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation 101 (2000), 969–974.
145. Goldberg, R.J., Seeley, D., Becker, R.C., et al. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J 119 (1990), 996–1001.
146. Behar, S., Zahavi, Z., Goldbourt, U., et al. Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. SPRINT Study Group. Eur Heart J 13 (1992), 45–50.
147. ACTIVE Investigators Connolly, S.J., Pogue, J., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360 (2009), 2066–2078.
148. You, J.J., Singer, D.E., Howard, P.A., et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141 (2012), e531S–e575S.
149. Pisters, R., Lane, D.A., Nieuwlaat, R., et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138 (2010), 1093–1100.
150. Lopes, R.D., Rordorf, R., De Ferrari, G.M., et al. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol 71 (2018), 1063–1074.
151. Vamos, M., Erath, J.W., Hohnloser, S.H., Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J 36 (2015), 1831–1838.
152. Pedersen, O.D., Bagger, H., Køber, L., et al. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evaluation. Eur Heart J 20 (1999), 748–754.
153. McMurray, J., Køber, L., Robertson, M., et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45 (2005), 525–530.
154. Fauchier, L., Lecoq, C., Ancedy, Y., et al. Evaluation of 5 prognostic scores for prediction of stroke, thromboembolic and coronary events, all-cause mortality, and major adverse cardiac events in patients with atrial fibrillation and coronary stenting. Am J Cardiol 118 (2016), 700–707.
155. Álvarez-Álvarez, B., Raposeiras-Roubín, S., Abu-Assi, E., et al. Is 6-month GRACE risk score a useful tool to predict stroke after an acute coronary syndrome?. Open Heart, 1, 2014, e000123.
156. Bristol-Myers Squibb. A study of apixaban in patients with atrial fibrillation, not caused by a heart valve problem, who are at risk for thrombosis (blood clots) due to having had a recent coronary event, such as a heart attack or a procedure to open the vessels of the heart. Available at: https://www.clinicaltrials.gov Identifier: NCT02415400. Accessed November 1, 2017.
157. Daiichi Sankyo, Inc. Edoxaban treatment versus vitamin K antagonist in patients with atrial fibrillation undergoing percutaneous coronary intervention (ENTRUST-AF-PCI). Available at: https://www.clinicaltrials.gov Identifier: NCT02866175. Accessed November 1, 2017.
158. Boriani, G., Glotzer, T.V., Santini, M., et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke prevention Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J 35 (2014), 508–516.
159. Glotzer, T.V., Daoud, E.G., Wyse, D.G., et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2 (2009), 474–480.
160. Glotzer, T.V., Hellkamp, A.S., Zimmerman, J., et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 107 (2003), 1614–1619.
161. Healey, J.S., Connolly, S.J., Gold, M.R., et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366 (2012), 120–129.
162. Martin, D.T., Bersohn, M.M., Waldo, A.L., et al. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur Heart J 36 (2015), 1660–1668.
163. Sanna, T., Diener, H.-C., Passman, R.S., et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 370 (2014), 2478–2486.
164. Halcox, J.P.J., Wareham, K., Cardew, A., et al. Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF Study. Circulation 136 (2017), 1784–1794.
165. Bumgarner, J.M., Lambert, C.T., Hussein, A.A., et al. Smartwatch algorithm for automated detection of atrial fibrillation. J Am Coll Cardiol 71 (2018), 2381–2388.
166. Abed, H.S., Wittert, G.A., Leong, D.P., et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 310 (2013), 2050–2060.
167. Pathak, R.K., Middeldorp, M.E., Lau, D.H., et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol 64 (2014), 2222–2231.
168. Pathak, R.K., Middeldorp, M.E., Meredith, M., et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol 65 (2015), 2159–2169.
169. Abed, H.S., Samuel, C.S., Lau, D.H., et al. Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. Heart Rhythm 10 (2013), 90–100.
170. Wang, T.J., Parise, H., Levy, D., et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 292 (2004), 2471–2477.
171. Wong, C.X., Ganesan, A.N., Selvanayagam, J.B., Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions. Eur Heart J 38 (2017), 1294–1302.
172. Wong, C.X., Abed, H.S., Molaee, P., et al. Pericardial fat is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol 57 (2011), 1745–1751.
173. Middeldorp, M.E., Pathak, R.K., Meredith, M., et al. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. Europace 20 (2018), 1929–1935.